Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering better commercial prospects.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Image source: Getty Images. Weight-management leaders like Eli Lilly have been seeking a solution to this problem, and the healthcare specialist may have made an important step in that direction.

Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits ...

Though Novo Nordisk sells an oral form of semaglutide, it involves strict food and water guidelines. The potential Lilly product doesn't, offering it a significant advantage.

Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles.

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).

Biotech J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus By Gabrielle Masson May 13, 2025 7:00am Emerging Biopharma Cell & Gene Therapy RA Capital BlueRock ...